摘要
目的探讨瑞舒伐他汀对急性脑梗死患者血清S100β、NSE、s ICAM-1、MMP-2、hs-CRP的影响。方法选取我院2010年9月至2014年9月收治的急性脑梗死患者90例,随机分为观察组和对照组,每组45例,两组均给予阿司匹林、舒血宁等常规治疗,另外,观察组和对照组同时给予瑞舒伐他汀20 mg、10 mg口服,比较两组患者治疗前后的NIHSS评分,同时比较两组治疗前及治疗后14 d两组患者血清S100β、NSE、s ICAM-1、MMP-2、hs-CRP水平。结果治疗前,两组NIHSS评分及血清S100β、NSE、s ICAM-1、M M P-2、hs-CRP水平比较差异无统计学意义。治疗后,观察组NIHSS评分低于对照组(P<0.05),血清S100β[(0.08±0.05)μg/L]、NSE[(7.34±1.33)μg/L]、s ICAM-1[(104.68±10.51)μg/L]、M M P-2[(466.36±79.00)μg/L]、hs-CRP[(5.43±0.56)μg/L]低于对照组[(0.11±0.06)、(8.46±1.80)、(131.91±11.44)、(519.46±81.01)、(7.30±0.80)μg/L],两组比较差异有统计学意义(P<0.05或P<0.01)。结论瑞舒伐他汀可显著改善急性脑梗死患者的临床症状,降低血清S100β、NSE、s ICAM-1、MMP-2、hs-CRP水平,值得在临床治疗上予以推广。
Objective To investigate the effect of rosuvastatin on serum S100β,NSE,s ICAM-1,MMP-2,hsCRP in patients w ith acute cerebral infarction. Methods A total of 90 patients w ith acute cerebral infarction in our hospital from September 2010 to September 2014 w ere randomly divided into tw o groups,and both groups w ere given aspirin,Shuxuening and other conventional treatment. In addition,patients in observation group and control group w ere given rosuvastatin w ith 20 mg and 10 mg orally. The changes of NIHSS score and the serum S100β,NSE,s ICAM-1,MMP-2,hs-CRP level w ere compared before and after treatment. Results There w as no significant difference in serum S100β,NSE,s ICAM-1,MMP-2 and hs-CRP betw een the tw o groups（ P〈0. 05）. After treatment,the NIHSS in observation group w as low er than that of control group,and the levels of S100β,NSE,s ICAM-1,MMP-2,hs-CRP in observation group w ere low er than those of control group：（ 0. 08 ± 0. 05） μg / L vs.（ 0. 11 ± 0. 06） μg / L,（ 7. 34 ± 1. 33）μg /L vs.（ 8. 46 ± 1. 80） μg /L,（ 104. 68 ± 10. 51） μg /L vs.（ 131. 91 ± 11. 44） μg /L,（ 466. 36 ± 79. 00） μg /L vs.（ 519. 46 ± 81. 01） μg /L,（ 5. 43 ± 0. 56） μg /L vs.（ 7. 30 ± 0. 80） μg /L,there were significant differences between the tw o groups（ P〈0. 05 or P〈0. 01）. Conclusion Rosuvastatin treating acute cerebral infarction could significantly improve the clinical symptoms,decrease the level of serum S100β,NSE,s ICAM-1,mmp2,hs-CRP,w orth of promotion in clinical treatment.
出处
《实用药物与临床》
CAS
2015年第7期777-780,共4页
Practical Pharmacy and Clinical Remedies
